Davis Polk advised Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to approximately HK$4.05 billion (US$523 million) prior to any exercise of the over-allotment option.

Shenzhen Hepalink is a leading China-based pharmaceutical company listed on the Shenzhen Stock Exchange with global pharmaceutical, innovative biotech and CDMO businesses. Founded by a group of seasoned polysaccharide-chemists with scientific insights and profound understanding of immunology, it has built up a portfolio of both leading drugs in the anticoagulant and antithrombotic therapeutic areas and innovative drug candidates focusing on diseases with an immune system disorder axis, including oncology, autoimmune, metabolic and other areas.

The Davis Polk corporate team included partners Li He and Yang Chu, registered foreign lawyer Jennifer Liu and Xiushan Sun and associates Lillian Lian, Cathy Yuen, Lydia Leung and Ray Ng. Associate Omer Harel provided tax advice. Members of the Davis Polk team are based in the Hong Kong and London offices.

Copy link to share post